ArticleScientific reports2025
3D-printed setup for ocular drug delivery evaluation on ex vivo porcine whole eye.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Reaching the back of the eye without invasive intraocular injections is still nowadays challenging. Luckily, the nanotechnology can help in improving the effectiveness and the patient compliance and, ultimately, the therapeutic success rate. The development and characterization of ophthalmic (nano)formulations benefit from the implementation of ex vivo models, that allow to disclose the formulation behaviour once in contact with biological tissues and consequently its optimization. Ex vivo ocular models help to minimize the number of promising formulations deserving to be investigated in in vivo animal models, in compliance with the 3Rs principle, and therefore their availability is of paramount importance. In this research work, we present a 3D-printed reusable device designed to be used in a whole porcine eye bulbs setup comparing it with the Franz-cell. The device, produced by a Masked Stereolithography Apparatus, consists of two components, the Ocudonor, acting as a donor chamber for the formulation, and the Ocutainer, which simultaneously contains up to three ocular bulbs. The porcine eye setup was validated using a dexamethasone-loaded nanostructured lipid carriers for periocular administration and intended for the treatment of the posterior segment of the eye. The porcine whole eye model proved capable of preserving eye structure integrity for at least 18 hours and, unlike the Franz-cell, enabled the evaluation of the drug's lateral diffusion along the eye bulb.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.